(Stroke. 1995;26:1676-1682.)
© 1995 American Heart Association, Inc.
Articles |
PPBP [4-Phenyl-1-(4-phenylbutyl) Piperidine], a Potent 
-Receptor Ligand, Decreases Brain Injury After Transient Focal Ischemia in Cats
From the Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions (H.T., J.R.K., R.C.K., R.J.T.), and the Neuroimaging and Drug Action Section, Division of Intramural Research, National Institute on Drug Abuse (K.H., E.D.L.), Baltimore, Md.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Background and Purpose We tested the hypothesis that administration of 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), a potent
-receptor ligand, during transient focal ischemia
would affect early postischemic brain injury. Methods Halothane-anesthetized cats underwent left middle cerebral artery occlusion for 90 minutes followed by 4 hours of reperfusion. Control cats received saline (n=10). Experimental cats (2 groups, n=10 per group) were treated with PPBP at a rate of 0.1 µmol/kg per hour (PPBP-0.1) or administered 1 µmol/kg per hour (PPBP-1) intravenously from 75 minutes after initiation of ischemia and continuing during the 4 hours of reperfusion.
Results As measured by the microsphere method, blood flow to the ipsilateral caudate nucleus was decreased similarly in all groups during ischemia. Blood flow to the ipsilateral inferior temporal cortex was decreased during ischemia in all groups but was higher in cats subsequently treated with PPBP at the highest dose, even before drug administration. There was no difference in blood flow to the ipsilateral caudate nucleus or inferior temporal cortex (area of greatest cortical injury) during reperfusion. Triphenyltetrazolium-determined injury volume of the ipsilateral cerebral hemisphere (control, 29±5%; PPBP-0.1, 17±3%; PPBP-1, 6±1% of ipsilateral hemisphere; mean±SEM) and caudate nucleus (control, 49±5%; PPBP-0.1, 39±6%; PPBP-1, 25±5% of ipsilateral caudate nucleus) was less in cats treated with 1 µmol/kg per hour of PPBP compared with cats treated with saline. Cats treated with 0.1 µmol/kg per hour had a 45% smaller hemispheric injury volume than the control group without differences in intraischemic blood flow. Recovery of somatosensory evoked potential amplitude was greater in cats treated with PPBP-1 compared with control (control, 18±11%; PPBP-0.1, 30±14%; PPBP-1, 54±14% of baseline).
Conclusions These data indicate that -receptors may play an
important role in the mechanism of acute injury in both the cortex and
the caudate nucleus after 90 minutes of transient focal
ischemia in the cat. Because PPBP afforded protection when
administered at the end of ischemia and during reperfusion,
-receptors may contribute to the progression of injury in
ischemic border regions.
Key Words: cerebral blood flow • middle cerebral artery occlusion • sigma receptor • evoked potentials, somatosensory • triphenyltetrazolium staining
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Little is known about the role of
-receptors in the mechanism of brain injury from
ischemia. However, several pharmacological agents that were
originally believed to have neuroprotective properties because of
effects at the NMDA receptor also have reasonable affinities for
-receptors. For example, ifenprodil and its derivative SL 82.0715
have been found to decrease infarct volume in cats and rats exposed to
permanent focal ischemia.1 These agents appear to
act as noncompetitive antagonists in several models of NMDA
receptor–mediated activity in vivo and in vitro2 ; they
are also potent -receptor ligands at 37°C.3 Other
-receptor ligands have also shown promise as neuroprotective agents.
However, each of these agents was only evaluated in a gerbil model of
cerebral ischemia,4 5 6 which did not allow for
tight control of important physiological variables, or in a rat model
of anoxia,7 which may not be relevant to the clinical
condition of focal ischemia. Therefore, because neuroprotection
afforded by these drugs may have been secondary to effects on important
physiological variables (eg, brain temperature)
rather than on primary mechanisms that produce injury, further
evaluation of their efficacy in the setting of ischemia was
warranted.
In the present study we tested the hypothesis that the potent
-ligand PPBP3 would prevent early evidence of brain
injury in a well-characterized model of transient focal
ischemia. In addition to assessment of the volume of injury, we
also measured regional CBF to determine whether any observed protection
by PPBP was related to a more favorable redistribution of perfusion
during ischemia or reperfusion.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The study was conducted in accordance with National Institutes of Health guidelines for the use of experimental animals, and the protocols were approved by the Animal Care and Use Committee of The Johns Hopkins Medical Institutions.
Male cats weighing 2.3 to 5.4 kg were anesthetized with halothane in oxygen. They were orally intubated and mechanically ventilated to maintain PaCO2 at approximately 35 to 40 mm Hg. Anesthesia was maintained with halothane (1.0% to 1.5%) in oxygen-enriched air (FIO2, 0.35 to 0.40). The concentration of anesthetic was not altered during ischemia and reperfusion. The skeletal muscle relaxant pancuronium bromide (0.2 mg/kg IV) was administered as a single dose to prevent movement during electrocautery and muscle artifact during evoked potential monitoring.
Both femoral veins were catheterized for infusion of lactated Ringer's solution and drugs. Catheters placed in the descending aorta via a femoral artery were used for blood pressure measurement, arterial blood gas sampling, and withdrawal of reference blood samples during injection of radiolabeled microspheres. After left thoracotomy, a catheter was inserted into the left atrium for injection of radiolabeled microspheres. A vascular loop, placed around the descending aorta, was used for blood pressure control during the experimental protocol. The cat was turned prone and its head positioned in a stereotaxic frame approximately 4 cm higher than its heart. A thermistor placed in the right temporal epidural space was used to estimate brain temperature. Epidural temperature was maintained at 38.0±0.5°C with the use of a warming blanket and a heating lamp. The left MCA was exposed by a transorbital approach with the use of microsurgical techniques. To produce focal ischemia, the left MCA was occluded near its origin from the intracranial carotid artery with the use of a microvascular clip for 90 minutes.8 9 At 90 minutes of occlusion, the microvascular clip on the MCA was removed. Reperfusion was then initiated, and it lasted 240 minutes.
Arterial blood pressure was continuously monitored. Arterial pH, PaCO2, and PaO2 were measured with a self-calibrating electrode system (Radiometer ABL 3). Hemoglobin and arterial oxygen content were measured with a hemoximeter (model OSM3, Radiometer). Blood glucose was measured with a glucose analyzer (model 2300A, Yellow Springs Instruments). A multichannel signal averager (model CA-1000, Nicolet Biomedical Instruments) was used to measure the SEP with foreleg stimulation, as previously described.9 10 The amplitude to the peak of the first major negative wave was measured from the peak of the preceding positive wave.
Regional CBF was measured with radiolabeled microspheres (15.5±0.5 µm diameter; Du Pont–NEN Products) by the reference withdrawal method.11 Six radioactive isotopes (153Gd, 114mIn, 113Sn, 103Ru, 95Nb, 46Sc) were injected in random sequence into each animal. Approximately 1.5x106 microspheres were injected into the left atrium over a 20-second period, followed by a 5-mL saline flush. Reference blood samples were withdrawn from the aorta at 1.9 mL/min beginning 30 seconds before the injection and continuing for 90 seconds after the saline flush.
After baseline measurements were obtained, experimental cats were
assigned randomly to one of three groups. Investigators were blinded to
the treatment. Each cat was exposed to 90 minutes of left MCA occlusion
and 240 minutes of reperfusion. In each group, treatment with either
diluent (saline) or drug was begun at 75 minutes of MCA occlusion, and
the infusion was continued throughout reperfusion. In the control
group, the saline diluent was infused at a rate of 4 mL/h. In the
PPBP-0.1 group, 0.1 µmol/kg per hour (volume, 4 mL/h) of PPBP was
infused for 15 minutes of MCA occlusion and 240 minutes of reperfusion.
In the PPBP-1 group, 1 µmol/kg per hour (volume, 4 mL/h) of PPBP was
infused for 15 minutes of MCA occlusion and 240 minutes of reperfusion.
Cats that did not achieve at least 75% reduction in SEP amplitude with
MCA occlusion were excluded from the protocol before assignment to a
particular treatment group. All variables were measured at
baseline, at 30 and 90 minutes of left MCA occlusion, and at 60, 180,
and 240 minutes of reperfusion. Cats that did not demonstrate adequate
ischemia of the caudate nucleus ipsilateral to the occlusion
(blood flow 
80 mL/min per 100 g) or ipsilateral inferior
temporal cortex (blood flow 50 mL/min per 100 g) were excluded from
further study. This elimination was completed before the investigator
had knowledge of the treatment group and resulted in a similar number
of cats excluded from each group (control group, 4 cats; PPBP-0.1
group, 4 cats; PPBP-1 group, 5 cats).
In a separate cohort of cats, we also evaluated the effect of PPBP infusion without intervening ischemia. Three cats were treated with saline (4 mL/h), and three cats were treated with PPBP at a rate of 1 µmol/kg per hour (volume, 4 mL/h) for a total duration of 240 minutes. These cats were prepared as those in the ischemia protocol except that they did not undergo surgery for MCA exposure. They were, however, instrumented with a catheter (PE-50) in the superior sagittal sinus for measurement of cerebral venous oxygen content and calculation of CMRO2 (the product of blood flow to the cerebrum and the arterial minus sagittal sinus oxygen content difference). In these cats, all variables were recorded at baseline and at 15, 60, 120, 180, and 240 minutes of saline or PPBP infusion.
At the end of each protocol, cats were killed with intravenous potassium chloride. In cats exposed to ischemia the brain was removed and cut immediately into 12 uniform coronal sections 3 mm thick to estimate brain injury with the TTC (Sigma Chemical Co) technique12 13 as previously described.10 14 After injury volume was estimated, the slices of brain were placed in 10% buffered formalin for 1 to 2 days before sectioning for regional CBF measurement. Ipsilateral and contralateral temporal and parietal lobes of the middle four slices were sectioned into inferior temporal, temporal-parietal, and parietal cortex; ipsilateral and contralateral caudate nucleus, brain stem, and cerebellum also were taken. The arterial microsphere reference samples and weighed tissue specimens were counted in a multichannel autogamma scintillation spectroscopy system, and blood flow was calculated by the reference sample technique.11
Values are expressed as mean±SEM. Statistical comparison to assess changes in measured physiological variables and CBF within groups was performed by repeated-measures ANOVA. Comparison of physiological variables, blood flow, and injury volume between groups was achieved with one-way ANOVA. Post hoc analysis was performed with the Newman-Keuls test. Two-way ANOVA (brain section and treatment group) was used to determine the effect of drug treatment on regional injury volume. Statistical differences were considered significant at P<.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In nonischemic cats, there was no difference between groups in any physiological variable, in blood flow to any brain region, or in CMRO2 (Fig 1
). In particular, PPBP did not increase CBF in any
region.
|
There were no significant differences in baseline values of any
physiological variables among the three
experimental groups subjected to ischemia (Table 1). Likewise, arterial blood gas values and
hemoglobin and glucose concentrations were similar between groups
throughout ischemia and reperfusion. Although treatment with
PPBP was associated with decreased MABP compared with baseline and
compared with the control group at 180 and 240 minutes of reperfusion,
MABP was maintained consistently above 100 mm Hg throughout
reperfusion in all groups. Brain temperature was controlled at
approximately 38°C in all groups.
|
Values of blood flow to brain regions ipsilateral to MCA occlusion and
to the posterior fossa are given in Table 2. Baseline
blood flow was similar between groups in all regions. Reduction in
cortical CBF during left MCA occlusion was graded. The greatest
reduction occurred in the ipsilateral inferior temporal
cortex, and the smallest reduction was seen in the parietal cortex. By
chance, within each region there was also some variability in the
degree of blood flow reduction between groups. This variation was most
evident in the ipsilateral inferior temporal cortex and the
ipsilateral temporal parietal cortex. For example, even before drug
administration (30 minutes of ischemia) CBF was higher in the
PPBP-1 group compared with the control group. On the contrary, CBF to
the ipsilateral caudate nucleus was similarly reduced in all groups
during MCA occlusion. In addition, CBF to the contralateral hemisphere
and caudate nucleus was similar between groups during MCA occlusion
(data not shown). During reperfusion, blood flow to the ipsilateral
parietal cortex, at 240 minutes of reperfusion, was greater in animals
treated with PPBP-1 than animals in the control group. Otherwise there
were no differences between groups in regional CBF during
reperfusion.
|
Baseline amplitude (control, 44±6 µV; PPBP-0.1, 44±6 µV; PPBP-1, 37±5 µV) and latency (control, 11.8±0.2 ms; PPBP-0.1, 11.8±0.3 ms; PPBP-1, 12.4±0.2 ms) of the primary cortical SEP were not different among groups. Ipsilateral SEP amplitude decreased to the same extent during left MCA occlusion (control, 4±2% of baseline; PPBP-0.1, 8±3% of baseline; PPBP-1, 10±3% of baseline). Contralateral SEP amplitude was not affected by MCA occlusion. During reperfusion, recovery of SEP amplitude was incomplete in all groups. However, at 240 minutes of reperfusion recovery was greater in cats treated with PPBP-1 compared with the control group (control, 18±11% of baseline; PPBP-0.1, 30±14% of baseline; PPBP-1, 54±14% of baseline; control versus PPBP-1, P=.05 by Dunnett's one-tailed test). All cats had normal latency of the wave measured over the second cervical vertebra throughout the protocol.
Ipsilateral cerebral hemispheric injury volume was greater in the
control group compared with the PPBP-0.1 and PPBP-1 groups when
expressed in terms of absolute volume (control, 2685±486
mm3; PPBP-0.1, 1473±286 mm3; PPBP-1, 503±102
mm3) or as a percentage of total ipsilateral hemispheric
volume (Fig 2). In addition, injury volume of the
caudate nucleus in control cats (143±20 mm3) was greater
than that in cats treated with PPBP-1 (73±16 mm3) but not
PPBP-0.1 (122±21 mm3) (Fig 2). When injury volume was
analyzed separately for each of 12 coronal sections, injury was
reduced in the ipsilateral hemisphere and ipsilateral caudate nucleus
in the PPBP-1 group (two-way ANOVA) and in the ipsilateral hemisphere
in the PPBP-0.1 group (Fig 3).
|
|
Statistical significance of injury volume without significant
differences in CBF may arise from variability in
intraischemic CBF. To test the relationship between these
two parameters, we plotted individual volume in the primary
MCA territory (inferior temporal cortex) versus CBF in this
region at 30 minutes (before PPBP) and 90 minutes (15 minutes after
start of PPBP infusion) of occlusion (Fig 4). As
expected, injury volume was inversely related to CBF. When CBF was less
than 30 mL/min per 100 g, injury area was usually less in both the
PPBP-0.1 and PPBP-1 groups than in the control groups at matched levels
of CBF.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This study demonstrates that intravenous administration of PPBP beginning at 75 minutes after initiation of a 90-minute focal ischemic insult and continuing throughout 240 minutes of reperfusion substantially reduced the volume of acute brain injury. These results support a role of
-receptors in modulating
focal ischemic injury.
During MCA occlusion CBF was higher in cats that were to
subsequently receive the highest dose of PPBP. This finding was clearly
not a pharmacological effect because it was even observed before PPBP
administration (ie, at 30 minutes of ischemia). This difference
occurring by chance in predrug values of CBF was present in
cortical regions but not in the caudate nucleus, suggesting greater
variability of collateralization between animals in cortical regions
compared with subcortical regions. Thus, part of the 81% difference in
hemispheric injury volume seen in the PPBP-1 group may be attributable
to greater collateral blood flow occurring by chance in this group.
However, we believe that the major mechanism of action of PPBP is
independent of CBF for several reasons. First,
intraischemic CBF to the caudate nucleus was not different
between the control and PPBP-1 groups, yet caudate injury volume in the
treated group was 49% smaller than in controls. Second, at the lower
dose of PPBP there was no difference in intraischemic blood
flow in the cerebral cortex, yet hemispheric injury volume was 45%
smaller than in controls. Third, to ensure that these effects were not
due to an error arising from pooling of data, we plotted the individual
injury volume of the MCA territory versus CBF (Fig 4
) and found that
injury size was generally less with either dose of PPBP than in the
controls at equivalent levels of intraischemic CBF. Fourth,
the drug did not increase CBF in nonischemic brain regions
or in cats not subjected to ischemia. Fifth, only a small
fraction of the total dose of PPBP was administered during the last 15
minutes of ischemia, and there was no effect of PPBP on CBF
during reperfusion, when most of the drug was administered. Therefore,
although we cannot exclude some effect of PPBP on improving
intraischemic CBF, the major mechanism of action of the
drug appears to be independent of CBF.
A wealth of evidence has implicated -receptors in a variety of
physiological processes and pathological
conditions.15 16 17 18 These include psychosis, antipsychotic
actions of neuroleptic drugs, and motor, endocrine, and immune
functions. However, the role of -receptors in the mechanism of
ischemic brain injury has not been completely elucidated. For
example, although the -receptor ligand ifenprodil has efficacy in a
model of permanent focal ischemia in cats, the mechanism of
protection was believed to be due to inhibition at the polyamine
modulatory site of the NMDA receptor.1 The role of a
possible change in cerebral perfusion during drug administration was
not assessed. A variety of -receptor ligands have also been
evaluated in a gerbil model of transient ischemia. In this
model, it is very difficult to measure and control many important
physiological variables (eg, blood pressure,
brain temperature) that may have independent effects on brain
injury.
N-Allylnormetazocine [(+)SKF 10,047], a -ligand that is
also a noncompetitive NMDA receptor
antagonist,19 20 is neuroprotective in a
gerbil model of transient focal ischemia.21 22 The
mechanism of protection for (+)SKF 10,047 may be related to its ability
to prevent ischemia-induced increases in intracellular
calcium21 or its ability to prevent cortical spreading
depression.23 In addition, several drugs in a series of
U-50,488H analogues, which are potent -receptor ligands, manifested
significant efficacy in the gerbil model of transient ischemia,
whereas one compound in the series (BD-601) afforded no neuroprotection
despite marked affinity for -receptors.6 In models of
cerebral ischemia, factors that may influence the effects of
-receptor ligands include differential activities of these drugs at
-receptor subtypes18 24 and interactions with
neurotransmitter systems not directly related to -receptors.
Furthermore, although most evidence suggests that -receptor ligands
act in a manner similar to agonists, some reports suggest
antagonist actions of -compounds.18
These data do not completely exclude the possibility that PPBP is
eliciting its protective effects via a mechanism other than that
expected from a -receptor interaction. For example, other
-receptor ligands have been found to also be potent direct ligands
at a number of different receptors, including the NMDA receptor
complex.16 19 20 Because of these effects at other
receptors it has been very difficult to establish a definite
relationship between -receptor affinity and
neuroprotection.7 As PPBP is an extremely potent ligand at
-receptors3 and the binding of [3H]PPBP
is inhibited by a number of -ligands but not by many other
drugs,25 26 PPBP may be an appropriate agent to use to
assess the relationship between -receptor affinity and
neuroprotection.
We found no effect of PPBP on CBF or CMRO2. Contrary to
this finding, Altura et al27 have demonstrated cerebral
vasoconstriction of -ligands tested in vitro. This difference
between apparent cerebral vascular effects of -ligands may be due to
differences intrinsic to each drug. For example, some -ligands
decrease cerebral metabolism, whereas others increase
cerebral metabolism.28 Likewise, depending on
the -ligand studied, there is great variability in ability to
inhibit amine uptake and alter contractile responses of
arterial segments studied in vitro.29
Injury volume was estimated with TTC staining. TTC acts as a proton acceptor for mitochondrial oxidative cellular metabolism.30 When compared with light microscopy, TTC tended to overestimate ischemic volumes of hemispheres and cortex and underestimate ischemic volume in caudate for rats exposed to 4 hours of MCA occlusion.31 In another study, TTC staining was found to correlate with histopathology best in cats when the time of ischemia was greater than 2 hours and there was at least 2 hours of reperfusion.32 Bederson et al12 demonstrated that there was good correlation between TTC staining and histopathologic evaluation in rats exposed to 1 to 2 hours or 5 to 6 hours of MCA occlusion but not to 3 hours of MCA occlusion (sample size of only 3 for 3 hours). Nonetheless, since Cole et al13 have demonstrated that the histochemical abnormality revealed by TTC staining may not necessarily represent inevitable infarction when it is used for paradigms of short ischemic periods (3 hours in their study), we cannot be certain that the eventual injury, measured at a later time, would not be similar between groups. Therefore, our results may only indicate that rate of brain injury development is altered by PPBP treatment. However, an alteration in rate of injury may have important clinical implications, as it may increase the window of opportunity for use of other therapeutic agents.
In conclusion, PPBP is effective in decreasing brain injury from
transient focal ischemia, even when it is administered after
the onset of ischemia. The mechanism of protection does not
appear to be primarily related to a more favorable redistribution of
blood flow during ischemia or reperfusion. Rather, we speculate
that -receptors may modulate focal ischemic damage by
altering NMDA receptor function.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This study was supported by US Public Health Service, National Institutes of Health grant NS-20020 and the Division of Intramural Research of the National Institute on Drug Abuse. The authors thank Toshiki Okada, MD, and Ying Wu for their excellent technical assistance.
|
Footnotes |
|---|
Reprint requests to Jeffrey R. Kirsch, MD, Department of Anesthesiology and Critical Care Medicine, 600 N Wolfe St, Blalock 1410, Baltimore, MD 21287-4963.
Received January 6, 1995; revision received April 14, 1995; accepted May 23, 1995.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, Gaudilliere B, MacKenzie ET, Rousseau J, Scatton B, Wick A. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents, I: evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther. 1988;247:1211-1221.
2.
Carter C, Benavides J, Legendre P, Vincent JD, Noel F,
Thuret F, Lloyd KG, Arbilla S, Zivkovic B, MacKenzie ET.
Ifenprodil and SL 82.0715 as cerebral anti-ischemic
agents, II: evidence for N-methyl-D-aspartate receptor
antagonist properties. J Pharmacol
Exp Ther. 1988;247:1222-1232.
3.
Hashimoto K, London ED. Further
characterization of [3H]ifenprodil binding to
receptors in rat brain. Eur J Pharmacol. 1993;236:159-163. [Medline]
[Order article via Infotrieve]
4. Contreras PC, Gray NM, Ragan DM, Lanthorn TH. BMY-14802 protects against ischemia-induced neuronal damage in the gerbil. Life Sci. 1992;51:1145-1149. [Medline] [Order article via Infotrieve]
5.
Clissold DB, Pontecorvo MJ, Jones BE, Abreu ME, Karbon
EW, Erickson RH, Natalie KJ Jr, Borosky S, Hartman T, Mansbach RS,
Balster RL, Ferkany JW, Enna SJ. NPC 16377, a potent and
selective -ligand, II: behavioral and neuroprotective
profile. J Pharmacol Exp Ther. 1993;265:876-886.
6. Contreras PC, Raga DM, Bremer ME, Lanthorn TH, Gray NM, Iyengar S, Jacobson AE, Rice KC, de Costa BR. Evaluation of U-50,488H analogs for neuroprotective activity in the gerbil. Brain Res. 1991;546:79-82. [Medline] [Order article via Infotrieve]
7. Taylor DP, Yevich JP, Dextraze P, Moon SL, Behling SH, Defnet J, Geissler M. Sigma ligands: a role in neuroprotection? In: Kamenka J-M, Domino EF, eds. Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? Ann Arbor, Mich: NPP Books; 1992:767-778.
8.
OBrien MD, Waltz AG. Transorbital approach for
occluding the middle cerebral artery without craniectomy.
Stroke. 1973;4:201-206.
9.
Matsumiya N, Koehler RC, Traystman RJ.
Consistency of cerebral blood flow and evoked
potential alterations with reversible focal ischemia in
cats. Stroke. 1990;21:908-916.
10.
Matsumiya N, Koehler RC, Kirsch JR, Traystman RJ.
Conjugated superoxide dismutase reduces extent of caudate injury
after transient focal ischemia in cats.
Stroke. 1991;22:1193-1200.
11. Heymann MA, Payne BD, Hoffman JI, Rudolph AM. Blood flow measurements with radionuclide-labeled particles. Prog Cardiovasc Dis. 1977;20:55-79. [Medline] [Order article via Infotrieve]
12.
Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis
RL, Bartkowski HM. Evaluation of
2,3,5-triphenyltetrazolium chloride as a
stain for detection and quantification of experimental cerebral
infarction in rats. Stroke. 1986;17:1304-1308.
13. Cole DJ, Drummond JC, Ghazal EA, Shapiro HM. A reversible component of cerebral injury as identified by the histochemical stain 2,3,5-triphenyltetrazolium chloride (TTC). Acta Neuropathol. 1990;80:152-155. [Medline] [Order article via Infotrieve]
14.
Takeshima R, Kirsch JR, Koehler RC, Gomoll AW,
Traystman RJ. Monoclonal leukocyte antibody (MoAb 60.3) does not
decrease injury following transient focal cerebral ischemia in
cats. Stroke. 1992;23:247-252.
15. Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry. 1991;29:41-54. [Medline] [Order article via Infotrieve]
16. Su T-P. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol. 1993;7:187-203. [Medline] [Order article via Infotrieve]
17. Deutsch SI, Weizman A, Goldman ME, Morihisa JM. The sigma receptor: a novel site implicated in psychosis and antipsychotic drug efficacy. Clin Neuropharmacol. 1988;11:105-119. [Medline] [Order article via Infotrieve]
18. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev. 1990;42:355-402. [Medline] [Order article via Infotrieve]
19. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Neurosci. 1990;11:81-86.
20. Lysko PG, Feuerstein G. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor: protection by SKF 10.047. Neurosci Lett. 1990;120:217-220.[Medline] [Order article via Infotrieve]
21.
Lysko PG, Yue T-L, Gu J-L, Feuerstein G.
Neuroprotective mechanism of (+)SKF 10,047 in vitro and in
gerbil global brain ischemia. Stroke. 1992;23:1319-1324.
22.
Lysko PG, Gagnon RC, Yue T-L, Gu J-L, Feuerstein G.
Neuroprotective effects of SKF 10,047 in cultured rat cerebellar
neurons and in gerbil global brain ischemia.
Stroke. 1992;23:414-419.
23. Willette RN, Lysko PG, Sauermelch CF. A comparison of (+)SK&F 10047 and MK-801 on cortical spreading depression. Brain Res. 1994;648:347-351.[Medline] [Order article via Infotrieve]
24.
Wu X-Z, Bell JA, Spivak CE, London ED, Su T-P.
Electrophysiological and binding studies
on intact NCB-20 cells suggest presence of a low affinity
Sigma receptor. J Pharmacol Exp
Ther. 1991;257:351-359.
25.
Hashimoto K, Scheffel U, London ED. In
vivo labeling of receptors in mouse brain with
[3H]4-phenyl-1-(4-phenylbutyl)piperidine.
Synapse. 1995;20:85-90. [Medline]
[Order article via Infotrieve]
26. Hashimoto K, London ED. Characterization of [3H]4-phenyl-1-(4-phenylbutyl)-piperidine binding in rat brain. Soc Neurosci Abstr. 1993;19:1155. Abstract.
27.
Altura BT, Quirion R, Pert CB, Altura BM.
Phencyclidine (`angel dust') analogs and sigma opiate
benzomorphans cause cerebral arterial spasm.
Proc Natl Acad Sci U S A. 1983;80:865-869.
28.
della Puppa A, London ED. Cerebral
metabolic effects of ligands in the rat.
Brain Res. 1989;505:283-290. [Medline]
[Order article via Infotrieve]
29.
Massamiri T, Duckles SP. Multiple vascular
effects of Sigma and PCP ligands: inhibition of amine uptake
and contractile responses. J Pharmacol Exp
Ther. 1990;253:124-129.
30. Glenner GG. Tetrazolium salts. In: Little RD, ed. H.J. Conn's Biological Stains. Baltimore, Md: Williams & Wilkins; 1969:154-162.
31. Park CK, Mendelow AD, Graham DI, McCulloch J, Teasdale GM. Correlation of triphenyltetrazolium chloride perfusion staining with conventional neurohistology in the detection of early brain ischaemia. Neuropathol Appl Neurobiol. 1988;14:289-298. [Medline] [Order article via Infotrieve]
32. Liszczak TM, Hedley-Whyte ET, Adams JF, Han DH, Kolluri VS, Vacanti FX, Heros RC, Zervas NT. Limitations of tetrazolium salts in delineating infarcted brain. Acta Neuropathol (Berl). 1984;65:150-157. [Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  S. Yang, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch Cyclic Adenosine Monophosphate Response Element-Binding Protein Phosphorylation and Neuroprotection by 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Anesth. Analg., March 1, 2009; 108(3): 964 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang, A. Bhardwaj, J. Cheng, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch Sigma Receptor Agonists Provide Neuroprotection In Vitro by Preserving bcl-2 Anesth. Analg., May 1, 2007; 104(5): 1179 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Vagnerova, P. D. Hurn, A. Bhardwaj, and J. R. Kirsch Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase. Anesth. Analg., August 1, 2006; 103(2): 430 - 4, table of contents. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Goyagi, A. Bhardwaj, R. C. Koehler, R. J. Traystman, P. D. Hurn, and J. R. Kirsch Potent {sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Provides Ischemic Neuroprotection Without Altering Dopamine Accumulation In Vivo in Rats Anesth. Analg., February 1, 2003; 96(2): 532 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Goyagi, S. Goto, A. Bhardwaj, V. L. Dawson, P. D. Hurn, and J. R. Kirsch Neuroprotective Effect of {{sigma}}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production Stroke, July 1, 2001; 32(7): 1613 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Harukuni, A. Bhardwaj, A. B. Shaivitz, A. C. DeVries, E. D. London, P. D. Hurn, R. J. Traystman, J. R. Kirsch, and F. M. Faraci {sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl)-Piperidine Affords Neuroprotection From Focal Ischemia With Prolonged Reperfusion • Editorial Comment Stroke, April 1, 2000; 31(4): 976 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhardwaj, M. Sawada, E. D. London, R. C. Koehler, R. J. Traystman, J. R. Kirsch, and F. M. Faraci Potent {varsigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Modulates Basal and N-Methyl-D-Aspartate–Evoked Nitric Oxide Production In Vivo • Editorial Comment Stroke, November 1, 1998; 29(11): 2404 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kirsch, A. Bhardwaj, L. J. Martin, D. F. Hanley, and R. J. Traystman Neither L-Arginine nor L-NAME Affects Neurological Outcome After Global Ischemia in Cats Stroke, November 1, 1997; 28(11): 2259 - 2265. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. R. Whittemore, V. I. Ilyin, and R. M. Woodward Antagonism of N-Methyl-D-Aspartate Receptors by sigma Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 326 - 338. [Abstract] [Full Text]
|
|
|
|
|
|
H. Takahashi, J. R. Kirsch, K. Hashimoto, E. D. London, R. C. Koehler, R. J. Traystman, and P. G. Lysko PPBP [4-Phenyl-1-(4-phenylbutyl) Piperidine] Decreases Brain Injury After Transient Focal Ischemia in Rats Stroke, November 1, 1996; 27(11): 2120 - 2123. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Silve, P. H. Dupuy, C. Labit-Lebouteiller, M. Kaghad, P. Chalon, A. Rahier, M. Taton, J. Lupker, D. Shire, and G. Loison Emopamil-binding Protein, a Mammalian Protein That Binds a Series of Structurally Diverse Neuroprotective Agents, Exhibits Delta 8-Delta 7 Sterol Isomerase Activity in Yeast J. Biol. Chem., September 13, 1996; 271(37): 22434 - 22440. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||